Cyclerion Therapeutics, Inc. (NASDAQ:KRSA – Get Free Report)’s share price crossed above its 50 day moving average during trading on Monday. The stock has a 50 day moving average of $32.09 and traded as high as $34.18. Cyclerion Therapeutics shares last traded at $32.68, with a volume of 319,840 shares changing hands.
Analyst Upgrades and Downgrades
Several research firms have recently commented on KRSA. TD Cowen began coverage on shares of Cyclerion Therapeutics in a report on Monday, September 14th. They issued a “buy” rating on the stock. Wells Fargo & Company started coverage on shares of Cyclerion Therapeutics in a research note on Friday. They set an “overweight” rating and a $44.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cyclerion Therapeutics in a research note on Friday, July 24th. Wall Street Zen upgraded shares of Cyclerion Therapeutics to a “sell” rating in a report on Saturday, October 3rd. Finally, Zacks Research upgraded shares of Cyclerion Therapeutics to a “hold” rating in a research note on Wednesday, September 9th. One analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $51.20.
Check Out Our Latest Research Report on Cyclerion Therapeutics
Cyclerion Therapeutics Price Performance
The business’s 50 day moving average is $32.09. The stock has a market capitalization of $1.49 billion, a P/E ratio of -2.57 and a beta of 1.85.
Cyclerion Therapeutics (NASDAQ:KRSA – Get Free Report) last released its quarterly earnings data on Thursday, November 5th. The company reported ($3.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($50.40) by $47.21. As a group, equities analysts expect that Cyclerion Therapeutics, Inc. will post -5.35 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of institutional investors and hedge funds have recently modified their holdings of KRSA. Braidwell LP bought a new stake in Cyclerion Therapeutics in the second quarter worth $532,000. ADAR1 Capital Management LLC purchased a new stake in Cyclerion Therapeutics during the second quarter valued at $1,013,000. Finally, BlackRock Inc. purchased a new stake in Cyclerion Therapeutics during the second quarter valued at $57,000. 75.62% of the stock is owned by hedge funds and other institutional investors.
About Cyclerion Therapeutics
Cyclerion Therapeutics was a clinical-stage biotechnology company focused on developing medicines for serious disorders of the central nervous system. The company originated as a spinout from Ironwood Pharmaceuticals in 2019 and was based in Cambridge, Massachusetts. Its research centered on small-molecule drugs that stimulate soluble guanylate cyclase, an enzyme involved in cellular signaling. Cyclerion’s development portfolio included zagociguat, an investigational, brain-penetrant candidate studied for conditions including cognitive impairment associated with Alzheimer’s disease and other neurological disorders.
Further Reading
- Five stocks we like better than Cyclerion Therapeutics
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Cyclerion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cyclerion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
